Navigation Links
Infant Blood May Provide Insights into Diseases Present at Birth
Date:12/15/2008

GRAND RAPIDS, Mich., Dec. 15 /PRNewswire/ -- Van Andel Institute (VAI) researchers are the first to apply a new technology to measure on a large scale the presence of genes in blood spots - the blood drawn from newborn infants to screen for health-threatening conditions. Using a random sample of blood spots collected from 1998 to 2004 and the latest RNA technology, researchers were able to detect over 3,000 genes in each sample, and to quantify the levels of several specific genes. This type of testing and data could eventually be used for the retrospective study of disease with an ultimate goal of identifying at-risk children in an attempt to pre-empt the onset of disease.

"This is a vast, underutilized resource," said James Resau, Ph.D., distinguished scientific investigator, deputy director for special programs, and director of the Division of Quantitative Sciences at VAI. "Imagine testing blood from nearly the entire population of U.S. infants and using the data for the retrospective study of disease. If a particular disease pops up in a specific segment of the population, you could use the data to look for causes, biomarkers and potential drug targets."

All 50 states in the U.S. have mandatory newborn screening programs, and the practice has been adopted by most countries around the world. Typically, this involves pricking the heel of newborns, also known as a "heel stick," to get a few drops of blood on filter paper. The blood is then screened for diseases for which early diagnosis and therapy can cure, prevent, or lessen the effects of the disease. The list of diseases tested for varies by state, but testing generally only uses a small portion of the blood. The rest is archived in varying conditions, sometimes for 21 years or more.

"The amazing thing is that many of these blood spots are stored in room temperature conditions, so we're basically testing dried blood on filter paper," said Resau. "Even so, we got good RNA test results from samples that have been in storage for as long as nine years."

While other researchers have confirmed the stability of blood spot RNA and its ability to reflect diseases, VAI researchers are the first to apply the latest tools in RNA technology to measure the expression of genes in blood spots on a larger scale. Using a random sample of blood spots collected from 1998 to 2004, researchers were able to detect an average of 3,480 genes in each sample, and to quantify the levels of several specific genes. Researchers in VAI's Laboratories of Microarray Technology and Molecular Epidemiology led by Resau and lead author of the study, Peterson T. Haak, received valuable assistance and expertise from Nigel Paneth, M.D., and his colleagues at Michigan State University's College of Human Medicine, College of Osteopathic Medicine and Department of Physiology.

"By teaming with state health departments and utilizing existing blood spot archives, we hope to improve our understanding of diseases that are not immediately apparent at birth, but have roots in the perinatal period," said Resau. "Measuring the relative abundance of thousands of expressed genes from

universally collected neonatal blood spots may open new avenues of research into perinatal markers and determinants of disease development."

By state law in effect since 1986, the Michigan Department of Community Health stores blood spots for 21.5 years. Michigan state law explicitly encourages the use of these archived blood spots for medical research; anonymous samples can be obtained for research with approval from an Institutional Review Board and the Michigan Department of Public Health, and individually identified samples can be obtained with parental informed consent.

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.


Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
James Resau
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81557


'/>"/>
SOURCE Van Andel Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
2. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
3. Omega-3 Fatty Acids Critical to Infants, Mothers and the Seriously Ill
4. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
5. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
6. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
7. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
8. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
9. Pregnant Women Need Omega-3 to Boost Infant Development
10. Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities
11. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - Medical ... Devices sector report, "Aesthetic Devices - Medical Devices Pipeline ... in pipeline stage. This report is ... primary research by GlobalData,s team of industry experts. ... or altered based on the availability and relevance of ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016  Otsuka Pharmaceutical ... announced that they have entered into a licensing agreement ... in the U.S. and Puerto Rico ... a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new ... --> In a Phase II clinical ...
(Date:2/8/2016)... 2016  Echo Therapeutics, Inc. (Nasdaq: ... on non-invasive continuous glucose monitoring (CGM) and ... it will host a webcast and conference ... 9:00 a.m. Eastern Time to provide a ... advancements in its CGM system, and its ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... A new ... for Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, ... Montague, a 2003 graduate of FHU and the creator of GO! Camp, has been ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... staff helped give free oral screenings to 150 children in kindergarten through third ... The College of Dental Medicine joined Chinese American Dental Society of Southern California ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 09, 2016 , ... ... surgeons are witnessing a dramatic increase in the number of patients under the age ... reflects what they are seeing in their offices, and may indicate an overall shift ...
(Date:2/10/2016)... ... 2016 , ... Traumatic Brian Injury is often in the ... of many possible sources: sports, car accidents, falls, work accidents, combat and other ... Solutions for the Complexities of Concussions is designed for physical and occupational ...
Breaking Medicine News(10 mins):